Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed
with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted
multiphasic MRI imaging will be acquired in patients with radiological or histological
diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its
role in lesion detection, characterisation and staging in patients with HCC.